Verastem (NASDAQ:VSTM – Get Free Report)‘s stock had its “buy” rating restated by BTIG Research in a report released on Tuesday, Benzinga reports. They currently have a $27.00 price objective on the biopharmaceutical company’s stock. BTIG Research’s target price would indicate a potential upside of 318.60% from the company’s previous close.
A number of other analysts also recently issued reports on VSTM. B. Riley began coverage on shares of Verastem in a report on Wednesday, September 27th. They set a “buy” rating and a $21.00 price objective for the company. Mizuho reiterated a “buy” rating and set a $36.00 price target on shares of Verastem in a report on Tuesday, August 29th. StockNews.com lowered shares of Verastem from a “hold” rating to a “sell” rating in a report on Monday, November 13th. Truist Financial lowered their price objective on shares of Verastem from $39.00 to $34.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th. Finally, Royal Bank of Canada decreased their target price on Verastem from $34.00 to $32.00 and set an “outperform” rating for the company in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Verastem currently has a consensus rating of “Moderate Buy” and an average price target of $29.71.
Verastem Trading Up 1.9 %
Institutional Trading of Verastem
Several institutional investors and hedge funds have recently modified their holdings of VSTM. Maven Securities LTD purchased a new position in shares of Verastem in the second quarter worth $896,000. AlphaCentric Advisors LLC purchased a new stake in shares of Verastem during the 2nd quarter worth approximately $1,116,000. Arete Wealth Advisors LLC bought a new position in shares of Verastem during the 1st quarter valued at approximately $9,487,000,000. Virtu Financial LLC grew its holdings in shares of Verastem by 212.0% in the second quarter. Virtu Financial LLC now owns 41,048 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 27,890 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Verastem during the first quarter valued at $37,000. 75.25% of the stock is currently owned by institutional investors.
Verastem Company Profile
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK.
- Five stocks we like better than Verastem
- 5 Top Rated Dividend Stocks to Consider
- The only two airline stocks worth buying: One is a Goldman pick
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Ride the momentum: Apparel stocks soaring at 52-week highs
- Are Penny Stocks a Good Fit for Your Portfolio?
- Safeguard your portfolio with these three bargain stocks
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.